Skip to content
value.today

BioCorRx Inc.

BICX
$18 Mlast known market cap, Jul 2023 — no current value
Compare
World rank
—
no current market cap
Revenue
$1 M
For year ending December-2025
Net income
$-3 M
-430.0% margin
SEC filing
Employees
—

BioCorRx Inc. in brief

BioCorRx Inc. is a listed company in the Medical Care Facilities industry, based in Anaheim, California, USA. Its last known market value was $18 M (July 2023); there is no current figure. In the year to December 2025 it had sales of $1 M and a net loss of $3 M.

Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.

About BioCorRx Inc.

We were incorporated as Cetrone Energy Company on January 28, 2008 in the State of Nevada. From inception until we completed our reverse acquisition of Fresh Start Private, Inc., the principal business of the Company originally was to develop “green” renewable fuel sources for agricultural operations, specifically biodiesel. On July 26, 2010, we filed an amendment to our articles of incorporation changing our name to Fresh Start Private Management, Inc. During that time, we had no revenue and our operations were limited to capital formation, organization, and development of our business plan and target customer market. As a result of the reverse acquisition of FSP, on October 31, 2011, we ceased our prior operations and we are now a holding company and our wholly owned subsidiary engages in alcoholism and opioid addiction treatment through our BioCorRx® Recovery Program and related products.

From the company's annual report filed with the US SEC: read the report

BioCorRx Inc. timeline

4 events, 2008–2025
  1. 2008
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2010
  4. ✎
    Renamed Fresh Start Private Management, Inc.
    Formerly Cetrone Energy CO.
  5. 2014
  6. ✎
    Renamed BioCorRx Inc.
    Formerly Fresh Start Private Management, Inc..
  7. 2025
  8. 💰
    Record revenue of $1 million
    FY2025, the highest of the 8 years on record.

Events of BioCorRx Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$7 M$14 M$21 M$28 M2020202120222023

World rank over time

▼ down 4,210 places since 2020
2020-01-01: #25673#25,67320202021-01-01: #25673#25,67320212022-01-07: #30027#30,02720222022-12-25: #32359#32,35920222023-07-30: #29883#29,8832023

Rank in USA: #4,559 (Jan 2020) · #4,664 (Jan 2021) · #5,258 (Jan 2022) · #5,721 (Dec 2022) · #5,223 (Jul 2023)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
-430.0%
Operating margin
-603.8%
Return on equity
—
Liabilities / assets
635.8%
Net debt
$-0M
Revenue growth
+7900.0%
R&D / revenue
221.3%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $0M, net income $-7M$0MFY18Fiscal year ending Dec 2019: revenue $0M, net income $-6M$0MFY19Fiscal year ending Dec 2020: revenue $0M, net income $-4M$0MFY20Fiscal year ending Dec 2021: revenue $0M, net income $-5M$0MFY21Fiscal year ending Dec 2022: revenue $0M, net income $-4M$0MFY22Fiscal year ending Dec 2023: revenue $0M, net income $-4M$0MFY23Fiscal year ending Dec 2024: revenue $0M, net income $-5M$0MFY24Fiscal year ending Dec 2025: revenue $1M, net income $-3M$1MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$1M+7900.0%$-5M$-3M-430.0%
Dec 2024$0M-88.9%$-5M$-5M-51100.0%
Dec 2023$0M-57.1%$-4M$-4M-4188.9%
Dec 2022$0M+320.0%$-5M$-4M-2085.7%
Dec 2021$0M-58.3%$-6M$-5M-10420.0%
Dec 2020$0M-50.0%$-7M$-4M-2925.0%
Dec 2019$0M-36.8%$-6M$-6M-2520.8%
Dec 2018$0M—$-5M$-7M-1731.6%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-2M——$-0.19—
Dec 2024$-1M——$-0.49—
Dec 2023$-2M————
Dec 2022$-2M$0M$-2M——
Dec 2021$-4M$0M$-4M$-0.81—
Dec 2020$-2M$0M$-2M$-0.65—
Dec 2019$-3M$-0M$-3M$-1.71—
Dec 2018$-2M$0M$-2M$-2.60—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-1M—Dec ’24Three months to Mar 2025: revenue $0M, net income $-1M$0MMar ’25Three months to Jun 2025: revenue $0M, net income $-1M$0MJun ’25Three months to Sep 2025: revenue $0M, net income $-1M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue $0M, net income $-1M$0MDec ’25Three months to Mar 2026: revenue $0M, net income $-1M$0MMar ’26Three months to Jun 2026: revenue $0M, net income $-1M$0MJun ’26Three months to Sep 2026: revenue —, net income $-1M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of BioCorRx Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$1 M
Operating income
$-5 M
Net income
$-3 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$2 M
Total liabilities
$14 M
Total equity
$-11 M

As of December-2025

Insider trading at BioCorRx Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
9
since
BioCorRx Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Lourdes FelixCEO and CFO, DirectorGrant or award+13,158——843,578Form 4
filed Louis C. LucidoPresident, Director, 10% ownerGrant or award+43,860——2.50 MForm 4
filed Louis C. LucidoPresident, Director, 10% ownerGrant or award+13,158——2.51 MForm 4
filed Louis C. LucidoPresident, Director, 10% ownerGrant or award+55,494——2.45 MForm 4
filed Louis C. LucidoPresident, Director, 10% ownerGrant or award+55,556——2.40 MForm 4
filed Louis C. LucidoPresident, Director, 10% ownerGrant or award+1.11 M——2.34 MForm 4
filed Lourdes FelixCEO and CFO, DirectorGrant or award+15,625——830,420Form 4
filed Louis C. LucidoPresident, Director, 10% ownerGrant or award+52,085——1.22 MForm 4

BioCorRx Inc. scorecard#

Passes 1 of the 9 checks that could be worked out: strongest in growth (1 of 3), weakest in financial health (0 of 3). Fiscal year 2025.

  • Valuationnot known
  • Growth1 of 3
  • Profitability0 of 2
  • Financial health0 of 3
  • Shareholder returns0 of 1

Worked out from the statements as filed (sec), the medians of Medical Care Facilities, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

BioCorRx Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

BioCorRx Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue7977.78921448123240377657702
Cost of revenue—1.73615r5.99682171324175
Research and development1,7691,4838911,4591,6064,2741,125152451—
Selling, general and administrative3,7943,6122,8753,4103,741—————
General and administrative————3,7413,1684,5654,4232,7402,545
Operating expenses5,6295,1303,8774,9125,5587,6155,8025,0033,5482,884
Operating income−4,832−5,123−3,788−4,698−5,510−7,492−5,561−4,626−2,891−2,182
Interest expense and finance costs224777194151195111,622r−1,959r11,1491,048
Net interest income————−566−511————
Non-interest income—1063.67.42.434————
Other non-operating income (expense)1,323−90173212993,985−487−1,958−26,815−3,722
Income before tax−3,509−5,212−3,770−4,377−5,211—————
Income tax0000000———
Net income including minority interests−3,509−5,212−3,770−4,377r5,211—————
Minority interests' share of net income−69−106——−5,278−3,472−6,040−6,512−29,706—
Net income attributable to shareholders−3,440−5,106r−3,770−4,377−5,211−3,507−6,048−6,584−29,706−5,904
Earnings per share, basic————-0.81-0.65-1.71-2.60-12.77r-0.03
Earnings per share, diluted-0.19-0.49——-0.81-0.65-1.71-2.60-12.77r-0.03
Shares, weighted average (diluted)1810r2.71.41.11.11.12.4r1.8r250
Balance sheet
Cash and cash equivalents139886569865922,6462801192
Receivables25300.735——————
Inventory1430————————
Current assets8141181873172289753,04731955101
Property, plant and equipment4.1195177103129148441922
Right-of-use (leased) assets15919997270385490459———
Goodwill5630————————
Other intangible assets5647.89.0100177224—252—
Long-term investments———45454542131318
Total assets2,1473863897678201,8273,933628339470
Accounts payable4,0293,0242,4732,0131,777r1,181709656r715768r
Current liabilities8,3068,2086,4315,3644,3863,0522,5516,1271,6382,451
Lease liabilities (non-current)11615911181316435428———
Total liabilities13,67412,74110,3418,9687,7816,0374,9926,3354,2328,601
Retained earnings−86,649−83,209−78,103−74,336−69,967−64,688−61,216r−55,176−48,841−19,135
Shareholders' equity−11,224−12,120−9,824−8,076r−6,961r−4,210r−1,059r−5,706−3,893−8,130
Minority interests−303−235−129−125−118−115−81r−72——
Total equity−11,527−12,355−9,953r−8,202−6,961−4,210r−1,059r−5,634−3,893—
Total liabilities and equity2,1473863897678201,8273,933628339470
Shares outstanding24138.77.76.75.55.32.62.4r182
Cash-flow statement
Depreciation and amortization443327276477297.43430
Share-based compensation5931,219r2773552103551,9662,807831582r
Cash from operating activities−2,298−1,096−1,853−2,042−3,538−2,152−2,937−1,826−2,540−1,999r
Capital expenditure———0−2.0r0−123−10−3.0−306
Intangible assets bought———0−48——−15——
Cash from investing activities———0−50−9.2−122−56−3.0−328r
Shares issued—700—1,2502,25001001,400940100
Cash from financing activities2,3501,1191,8502,0253,0811075,4252,1502,4122,250r
Change in cash————−506−2,0542,366268−131−78r
Report10-Q10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

As of Jun 30, 2026

Events at BioCorRx Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling

Auditor changed 2 · Directors and officers 6 · Material agreement 9 · Unregistered share sale 6

BioCorRx Inc.: events reported to the SEC
FiledWhat happenedFiling
Directors and officers8-K
Material agreementUnregistered share sale8-K
Material agreementUnregistered share sale8-K
Material agreementUnregistered share sale8-K
Auditor changed8-K
Directors and officers8-K
Directors and officers8-K
Material agreementUnregistered share sale8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Material agreement8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Auditor changed8-K
Material agreement8-K
Directors and officers8-K
Material agreement8-K

As of Sep 4, 2026

How BioCorRx Inc. compares in Medical Care Facilities

  • Revenue$1 M · higher than 1% of 133
  • Net margin-400.0% · higher than 1% of 127

Peer comparison · Medical Care Facilities

CompanyMarket capP/ENet marginRev. growth
BioCorRx Inc.🇺🇸$18 M—-400.0%—
HCA Healthcare, Inc.🇺🇸$96.8 B14.3×8.6%+7.1%
Fresenius SE & Co. KGaA🇩🇪$30.7 B20.4×5.5%-3.4%
Dr. Sulaiman Al Habib Medical Services Group Company🇸🇦$22.2 B34.6×17.5%+9.6%
Tenet Healthcare Corporation🇺🇸$21.4 B5.6×17.2%+3.1%
IHH Healthcare Berhad🇲🇾$18.1 B34.8×8.2%—
JD Health International Inc.🇨🇳$15.7 B20.2×7.3%—
Apollo Hospitals Enterprise Limited🇮🇳$14.3 B68.1×7.8%—
Fresenius Medical Care AG🇩🇪$12.4 B11.3×5.0%+5.8%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

How current the figures are

Market cap:
Jul 30, 2023 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 22, 2026

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at BioCorRx Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show BioCorRx Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about BioCorRx Inc.? Suggest a correction